New stroke drug LT3001 passes first safety check in healthy volunteers
NCT ID NCT04809818
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tested the safety of LT3001, a potential clot-busting drug for acute ischemic stroke, in 65 healthy adults. Participants received multiple doses of LT3001 alone or with common stroke medications like aspirin and clopidogrel. The goal was to check for side effects and how the drug interacts with other treatments, not to measure effectiveness against stroke.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LT3001 injection
- What this could lead to
- If successful, this could pave the way for a new stroke treatment that dissolves clots and may be safer when used with other medications.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not stroke patients. It only tests safety and drug interactions, not whether LT3001 actually treats strokes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lumosa Phase 1 Unit
Cypress, California, 90630, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?